Market Overview

Deutsche Bank Reiterates Buy Rating, $48 PT on Gilead Sciences on IMS Weekly Script Analysis

Share:
Related GILD
Assessing The Legitimacy Of The Biotech ETF Bounce
How Incyte Just Became A Major M&A Target
Trump As Reagan 2.0 - The Analogy Is Working: What's Next (Seeking Alpha)

In a report published Monday, Deutsche Bank reiterated its Buy rating and $48.00 price target on Gilead Sciences (NASDAQ: GILD).

Deutsche Bank noted, “Analysis of IMS Weekly scripts for week 9 of 1Q:13 (week 9 of 13) indicates that GILD's HIV franchise at $1,228.8M is tracking $66.4M better than consensus of $1,162.4M. Both Atripla &Truvada are tracking better than our projections respectively by +$22.1M & +$33.0M. Price increases were taken Jan 1 2013 on Truvada, Atripla, Complera, Viread, and Emtriva. This is additive to 1Q13 sales. Without these price increases, sales (ex-Stribild) would be tracking roughly $12.9M above consensus. Though early in launch, Stribild is tracking $21.4M better than consensus of $62.2M in 1Q13.”

Gilead Sciences closed on Friday at $45.43.

Latest Ratings for GILD

DateFirmActionFromTo
Nov 2016Stifel NicolausInitiates Coverage OnBuy
Nov 2016MizuhoInitiates Coverage OnBuy
Nov 2016BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!